Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

First Turn Management, LLC

CIK 0001993440
$895.1M
Reported AUM
33
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · First Turn Management, LLC · Q1 2026

AI · grounded in 13F

First Turn Management, LLC closed its position in GH for a reduction of $27.7M. The fund established several new positions, including ELVN for $24.5M and CELC for $24.0M. Additionally, the fund accumulated shares of UTHR, increasing its position by 64.7%.

Portfolio · Q1 2026

UTHR$62.1MABVX$51.9MBBIO$51.7MXENE$45.8MRVMD$45.5MAPGEINSMNUVLMIRMCOGTROIVAXSMOther$378.0MFL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1UTHRUNITED THERAPEUTICS CORP DEL$517.71-1.54%75.96%140.98%$62.1M6.94%HELD
2ABVXABIVAX SA$124.920.47%72.81%1124.93%$51.9M5.80%HELD
3BBIOBRIDGEBIO PHARMA INC$80.09-2.50%68.44%59.23%$51.7M5.77%HELD
4XENEXENON PHARMACEUTICALS INC$62.67-2.37%110.46%263.68%$45.8M5.11%HELD
5RVMDREVOLUTION MEDICINES INC$187.53-2.41%424.62%560.61%$45.5M5.09%HELD
6APGEAPOGEE THERAPEUTICS INC$134.09-0.16%255.38%484.81%$43.2M4.83%HELD
7INSMINSMED INC$98.60-2.85%-10.07%248.61%$40.6M4.54%HELD
8NUVLNUVALENT INC0.00%$37.9M4.24%HELD
9MIRMMIRUM PHARMACEUTICALS INC$105.95-5.90%108.58%567.72%$37.0M4.13%HELD
10COGTCOGENT BIOSCIENCES INC$38.93-5.88%248.33%379.59%$36.5M4.07%HELD
11ROIVROIVANT SCIENCES LTD$33.91-1.77%199.47%240.40%$33.0M3.68%HELD
12AXSMAXSOME THERAPEUTICS INC.$217.99-7.10%116.13%767.06%$31.9M3.56%HELD
13IDYAIDEAYA BIOSCIENCES INC$35.50-2.47%49.98%54.89%$29.1M3.25%HELD
14ORICORIC PHARMACEUTICALS INC$11.07-4.90%15.02%-47.31%$25.6M2.86%HELD
15ELVNENLIVEN THERAPEUTICS INC$54.811.59%188.04%181.58%$24.5M2.73%HELD
16CELCCELCUITY INC$86.38-1.44%119.59%298.36%$24.0M2.69%HELD
17SRRKSCHOLAR ROCK HLDG CORP$47.29-3.46%34.74%23.93%$21.9M2.45%HELD
18KYMRKYMERA THERAPEUTICS INC$103.40-3.37%140.11%66.00%$21.2M2.37%HELD
19CYTKCYTOKINETICS INC$77.13-4.09%112.78%136.79%$18.7M2.09%HELD
20DNTHDIANTHUS THERAPEUTICS INC$106.92-5.08%447.06%10.00%$18.5M2.07%HELD
21PVLAPALVELLA THERAPEUTICS INC NE$139.04-7.42%291.11%-66.85%$18.5M2.06%HELD
22NAMSNEWAMSTERDAM PHARMA COMPANY$27.79-2.35%33.74%194.62%$17.9M2.00%HELD
23VRDNVIRIDIAN THERAPEUTICS INC$18.92-4.92%14.30%48.73%$17.8M1.99%HELD
24ASNDUSDASCENDIS PHARMA A/S$17.5M1.95%HELD
25FULCFULCRUM THERAPEUTICS INC$3.58-3.76%-45.53%-87.47%$17.3M1.93%HELD
26430TERNS PHARMACEUTICALS INC$17.2M1.92%HELD
27VERAVERA THERAPEUTICS INC$32.10-2.87%54.11%119.03%$17.0M1.90%HELD
28NTRANATERA INC$267.76-0.70%100.37%127.70%$16.2M1.81%HELD
29ERASERASCA INC$18.15-2.84%1243.88%-21.87%$14.0M1.57%HELD
30PRAXPRAXIS PRECISION MEDICINES I$307.830.03%464.91%2.52%$13.7M1.53%HELD
31OLMAOLEMA PHARMACEUTICALS INC$11.45-3.13%$11.5M1.28%HELD
32QUREUNIQURE NV$43.633.41%$10.1M1.12%HELD
33MLTXMOONLAKE IMMUNOTHERAPEUTICS$18.44-2.90%$5.9M0.66%HELD

Source: SEC EDGAR · accession 0001993440-26-000002. 13F discloses long positions only — shorts, foreign equities, and options are excluded.